Today, physicians have two main options for monitoring a patient’s heart rhythm over time: short-term Holter monitors, which capture anywhere from 24 hours to two weeks of data, or implantable loop recorders, which require a surgical procedure. For many patients – especially those with intermittent symptoms, a history of stroke, or a recent cardiac procedure – neither option is quite right.
To understand where an AI-powered, non-invasive, long-term monitoring solution like Kardi AI fits into this picture, HITLAB conducted in-depth interviews with three practicing cardiologists across different clinical settings. Kardi AI pairs an ECG sensor worn on a chest strap with a mobile app and AI analysis of the ECG recordings, so patients can be monitored during their normal daily activities. The cardiologists’ feedback affirms a clear and consistent message: long-term, non-invasive cardiac monitoring fills a real and underserved need in patient care.
“Long-term, non-invasive EKG monitoring has a lot of space, especially in stroke patients. Every stroke patient should have long-term EKG monitoring… I think that adds a huge value to patient care.” – Dr. Yasar Sattar, Interventional & General Cardiologist
“I think right now the current options are either a two-week Holter or an implantable device. So this fits a nice gap.” – Dr. Jeffrey Wessler, Cardiologist
What the cardiologists described is already visible in Kardi AI’s real-world use in Europe. In the Czech Republic, the platform is used in more than 70 hospitals and by over 20 corporate and employee-benefit partners, with more than 6,000 users to date. About a quarter of those users had possible arrhythmias flagged, including more than 500 findings classified as critical – exactly the kind of intermittent rhythm events that short-term monitoring can miss.
Kardi AI has since expanded into Slovakia, where it works with more than 20 physicians, mainly cardiologists, and operates in Poland, Romania and Bulgaria. In November 2026, the company closed a €5.3 million Series A round led by Callisto Health to fund further expansion across Europe and Asia, with Germany as a near-term priority and planned entry into India, the UAE and Singapore.
Across all three interviews, physicians converged on similar patient populations who stand to benefit from a solution like Kardi AI:
Comfort and simplicity came up again and again. Physicians who wore the device themselves as part of their evaluation, and those who reviewed the patient app closely, consistently described it as intuitive and comfortable. Because the ECG sensor sits on a chest strap, similar to those used for fitness tracking, rather than on adhesive electrodes, it avoids a common complaint with patch monitors: skin irritation that builds up over days and weeks of wear.
“I thought it was very, very intuitive, easy to use and understand.” – Dr. Jeffrey Wessler
“Another thing which I really like about your device is it doesn’t have a lot of patches. Patients typically hate patches, especially the older ones – a lot of my patients have rashes from them.” – Dr. Yasar Sattar
Physicians also highlighted the value of reliable, automatic cloud-based data transfer, which removes a common point of friction in remote monitoring – patients don’t need to think about how their data gets to their care team.
As part of each interview, physicians completed a standardized usability assessment — the same type of evaluation used across the medical device industry to benchmark how intuitive a product truly is. Across three independent physicians, evaluating the device separately and without seeing each other’s feedback, four things stood out as unanimous:
That kind of unanimous agreement is rare in physician usability testing, and it speaks to a product that was designed with the end user in mind from the start.
Cardiologists reported trusting the AI’s rhythm interpretation, particularly once they had the chance to cross-check its output against their own clinical judgment.
“I trusted it. It looks good. It seems accurate, and that’s what makes me trust it.” – Dr. Jeffrey Wessler
That trust reflects how Kardi AI is designed to be used. The platform does not diagnose; it supports clinical decisions by giving physicians continuous, AI-analyzed monitoring data, while the interpretation and the diagnosis stay with the physician.
Physicians interviewed said they would recommend Kardi AI to their patients without hesitation, citing ease of use, meaningful clinical data, and improved patient comfort as the driving factors.
Physician feedback also pointed to clear opportunities to strengthen Kardi AI as it scales to new markets, including the U.S. The most consistent recommendations across interviews were:
We see this as a strength of our development process: real-world physician input, gathered early and often, directly shaping the roadmap. Several of the cardiologists we interviewed have also offered to partner with us on future clinical validation studies – a testament to how much promise they see in this category of care, and a timely one, as Kardi AI’s new funding is directed in part toward validating the technology at scale and across patient groups.
The consistent takeaway from these interviews is that long-term, non-invasive cardiac monitoring – done well – has real potential to close a meaningful gap in how physicians detect and manage arrhythmias.
Kardi AI is also looking beyond detection. Co-founder and CEO Vlastimil Hrabal has described the company’s next step as moving from detecting rhythm disorders to identifying risk before an arrhythmia appears, using models that analyze multiple ECG measurements together. These predictive capabilities are still in development and will need clinical validation and regulatory approval before they are used in patient care – which is exactly where close collaboration with practicing cardiologists matters most.
Kardi AI is being built and refined in direct collaboration with the cardiologists who will use it, and their feedback continues to guide our path toward broader clinical adoption.
This summary reflects qualitative feedback from three independent physician interviews conducted by HITLAB in 2026. Individual physician perspectives may vary and should not be interpreted as generalized clinical consensus. Company usage, funding and expansion figures are as reported in November 2026.
Associate Director of Research, HITLAB
Share the article:
Explore Recent Posts